Lidocaine With Epinephrine Shortage: Evidence and Solutions

The shortage of lidocaine with epinephrine described by Bodie, Brodell, and Helms was not simply a temporary inconvenience for dermatology clinics. It exposed how dependence on a small number of manufacturers, upstream shortages of epinephrine, and waste-control policies can affect routine procedural care. The authors’ brief report, Shortage of lidocaine with epinephrine: Causes and solutions, is valuable because it connects pharmaceutical supply conditions with concrete changes in clinical workflow.

Study Background and Research Question

In 2017, United States clinicians experienced a persistent shortage of lidocaine combined with epinephrine. According to the reference study, only two pharmaceutical companies were producing this formulation for the US market at the time: Fresenius Kabi USA supplied brand-name Xylocaine with epinephrine, while Pfizer, originally through Hospira, supplied a generic product. Neither manufacturer could provide a reliable date for resolving backorders. These historical details are documented in the reference report and establish the setting for the authors’ analysis.

The report asks a practical question rather than a mechanistic one: how can dermatologists preserve the benefits of epinephrine-containing local anesthesia when supply is constrained? The clinical relevance is substantial. Plain lidocaine can produce local vasodilation, whereas epinephrine reduces cutaneous blood flow. Without the vasoconstrictor, procedures may involve more bleeding, a less clear operative field, shorter anesthetic duration, and potentially greater hematoma-related infection risk. The authors support these consequences through prior vascular and surgical literature cited in their article.

Key Innovation from the Reference Study

The innovation of this paper lies in treating drug conservation as an evidence-informed clinical design problem. Rather than proposing a single substitute, the authors outline several interventions that can be implemented at different points in the medication-use process: preparation, administration, vial management, and end-of-day inventory control.

This systems perspective is important. A shortage is amplified when every procedure uses more anesthetic than necessary or when a multidose vial is discarded after a small fraction has been withdrawn. The authors therefore shift attention from finding an immediate replacement to improving the efficiency of each available unit. Their recommendations are especially relevant to outpatient dermatology, where many procedures require only a small volume and where standardized local protocols can produce large cumulative effects.

Methods and Experimental Design Insights

This publication is a clinical practice analysis and correspondence-style report, not a randomized trial or a new laboratory experiment. The authors synthesize contemporary shortage information, medication-safety guidance, prior studies of multidose-vial contamination, research on epinephrine-mediated cutaneous blood-flow reduction, and reports concerning the stability of prefilled lidocaine syringes. The evidentiary structure is consequently mixed: some recommendations arise from published data, while others are reasoned operational proposals for clinics.

Several methodological features make the report useful for researchers evaluating translational workflows. First, it identifies the causal chain behind the shortage instead of treating availability as an isolated purchasing issue. Second, it links formulation choice to a measurable physiological outcome—local blood flow—and then to procedural consequences such as bleeding and anesthetic duration. Third, it distinguishes product stability from preservative or sterility policy. The cited literature suggests that lidocaine itself has antimicrobial properties and that prefilled syringes may remain microbiologically safe longer than routine clinic disposal practices imply; however, epinephrine potency declines over time, and formal compounding requirements still govern use.

For experimental planning, the paper demonstrates the value of recording more than the nominal anesthetic concentration. A reproducible workflow should document injection volume, lidocaine concentration, epinephrine dilution, vial type, preparation date, storage conditions, and discard criteria. These variables can affect both procedural performance and the interpretation of studies examining wound healing, local inflammation, hemostasis, or pain-related outcomes.

Protocol Parameters

• Injection volume: The authors suggest drawing 1.5 mL rather than 3 mL for a biopsy when that volume is clinically sufficient, reducing use by 50% according to the reference report.
• Multidose-vial stewardship: Avoid discarding a 20-mL multidose vial after withdrawing only 2–5 mL, but apply institutional infection-control, pharmacy, and compounding policies before changing practice.
• Dilution strategy: A 1:1 mixture of 1% lidocaine with epinephrine at 1:100,000 and normal saline produces 0.5% lidocaine with epinephrine at 1:200,000; the authors cite prior work indicating that this formulation preserves useful vasoconstrictor effects.
• Prefilled syringes: The report discusses evidence for longer microbiological safety of prepared syringes, while recommending use within 1–2 weeks when preserving epinephrine activity is a priority; applicable USP and local policies remain controlling.
• Substitution planning: Plain lidocaine may be an alternative when combination product is unavailable, but the team should anticipate more bleeding and potentially shorter anesthesia rather than treating it as pharmacologically equivalent.

Core Findings and Why They Matter

The first major finding is causal: the shortage arose from both discontinuation by several manufacturers and a separate shortage of epinephrine that created a manufacturing bottleneck. This dual explanation matters because increasing orders alone cannot solve a constraint located in upstream production. It also clarifies why clinicians may experience prolonged backorders even when demand for lidocaine itself has not changed substantially.

The second finding is that conservation can be clinically meaningful without abandoning epinephrine. Reducing the prepared volume for small procedures directly decreases consumption. The proposed lidocaine-saline dilution offers another route to extend supply while retaining vasoconstrictor activity, although concentration changes must be validated within the intended procedure and governed by local policy.

The third finding concerns waste. The authors argue that single-patient use rules applied rigidly to multidose vials can result in substantial disposal after minor procedures. They cite a study reporting no bacterial or fungal contamination in the final dose of multidose vials used for specific immunotherapy, but that evidence should not be interpreted as universal proof of safety for every product, setting, or handling method. The paper’s practical message is to examine whether local procedures, training, and controlled access can reduce waste without compromising sterility.

Finally, the report warns against assuming that a prepared syringe remains equally effective throughout its storage period. Lidocaine stability and antimicrobial properties do not guarantee preservation of epinephrine activity. This distinction is important for studies and procedures in which vasoconstriction, hemostasis, or local exposure is a primary endpoint.

Comparison with Existing Internal Articles

The reference paper differs in emphasis from the internal article Advancing Translational Research with (-)-Epinephrine (+)-bitartrate. That article frames epinephrine as a research reagent across receptor biology and translational models, whereas Bodie and colleagues focus on formulation availability, clinical substitution, and supply stewardship. Reading them together helps separate two questions that are often conflated: how an adrenergic receptor agonist acts biologically, and whether an epinephrine-containing local anesthetic can be obtained, prepared, and used consistently.

Similarly, Reliable Cell Assays with (-)-Epinephrine (+)-bitartrate addresses assay reproducibility and concentration-controlled cell workflows. Its relevance here is methodological rather than evidentiary: both discussions show that preparation details and exposure conditions should be recorded explicitly. The shortage report, however, does not validate cell-based dosing schemes or establish receptor-specific experimental effects.

Limitations and Transferability

The report has several limitations. It reflects the US supply environment in 2017–2018, so manufacturer participation, availability, pricing, and regulatory interpretation may have changed. It also presents recommendations rather than comparative outcome data. The suggested volume reduction and dilution approach are plausible conservation measures, but the article does not provide a prospective trial comparing procedural pain, bleeding, anesthetic duration, infection, or patient satisfaction across all proposed strategies.

Recommendations concerning multidose vials and prefilled syringes require particular caution. Microbiological findings from one product category or clinical setting cannot automatically be generalized to another. Preparation technique, vial access frequency, preservatives, storage temperature, syringe materials, and institutional oversight may all influence risk. In research settings, any adaptation should be reviewed by pharmacy, infection-control, and regulatory personnel and documented in the study protocol.

Why this cross-domain matters, maturity, and limitations

The supply-stewardship lesson can inform sympathetic nervous system research, cardiovascular disease research, neurobiology studies, and work on the adrenergic signaling pathway, but only at the level of procurement and experimental reproducibility. The reference paper does not test receptor activation, cardiovascular endpoints, neural responses, or disease-modifying effects. Therefore, transfer to these fields is operationally mature—standardized preparation and inventory records are broadly useful—but biologically unproven by this publication.

Outlook

The reference study supports a restrained outlook: resilience is more likely to come from several modest interventions than from a single replacement product. Standardized volumes, transparent discard rules, validated dilution procedures, and explicit tracking of preparation age can reduce avoidable variation while supply conditions remain unstable. Future evaluations should focus on patient-centered and procedure-specific outcomes, especially whether conservation measures preserve hemostasis and anesthesia under real clinical conditions.

Research Support Resources

For laboratory workflows examining adrenergic responses or formulation-related vasoconstriction and bronchodilation, researchers can use (-)-Epinephrine (+)-bitartrate (SKU B1358), an Epinephrine Bitartrate preparation described as a non-selective adrenergic receptor agonist. The product information should be reviewed for handling, solubility, storage, and study-specific compatibility before use.